



hemotune raises CHF 14 million Series B2 funding for clinical trials with their disruptive blood purification platform

Schlieren, Switzerland, March 25th, 2024 – [hemotune AG](#), a pioneering Swiss biotech company, today announced the successful closing of a CHF 14 million Series B2 round dedicated to advancing its HemoSystem, a breakthrough blood purification platform based on nanoengineered magnetic beads. The investment was led by [Belmondo](#) with continued support of existing investors including [VP Venture Partners](#), [HEMEX](#), [OCCIDENT](#), [Zürcher Kantonalbank](#), and joined by [EFI](#).

The Series B2 funding round represents a significant step forward for hemotune, following the successful completion of preclinical development for their HemoSystem blood purification platform. This substantial investment will now allow the platform to move into clinical trials, marking a crucial phase in its development.

The HemoSystem stands out for its ability to effectively remove large biomolecules directly from patients' bloodstreams, offering a unique approach to implement precision medicine multi-target treatments which would not be possible through drugs. Initially focusing on treating sepsis-related immune suppression, hemotune also plans to explore other potential uses for the platform in the future. Given the serious impact of sepsis, which leads to around 11 million deaths annually and is a major economic burden, the potential benefits of this innovative technology are significant for patients and healthcare systems alike.

Lukas Langenegger, CEO and co-founder of hemotune AG, states: "I am immensely proud of our team's achievements in concluding the preclinical development of the HemoSystem. As we navigate through a challenging fundraising climate, the success of our Series B2 funding round underscores not only the potential of our innovative blood purification platform but also the confidence our backers have in our team and vision to revolutionize medical treatment."

Dr. Darius Madjdpour, founder at Belmondo comments: "The team of hemotune, through an impressive performance over the last 7 years, has managed to develop one of the most promising platform technologies I have seen in medicine. The possibilities to tackle various diseases and enabling therapies through HemoSystem has convinced us to take the lead in this funding round. We are happy to support the team for further journey and will be excited to see the product spread globally and help many patients over the coming years."

Cédric Barra, Senior Investment Manager at OCCIDENT: "This Series B2 funding will now pave the way for clinical trials. The company has done an excellent job over the last few years to get to this point and we hope that hemotune can make the therapy available to patients soon."

Dr. Annick Bay, Senior Associate of VP Venture Partners adds: "hemotune's precision blood purification system is designed to specifically remove individual proteins or combinations thereof, resulting in a medical device platform more akin to therapeutics developed by a traditional biotech, with the added benefit of a leaner development pathway for individual indications."



Pascal Winnen, CEO of HEMEX, asserts: "With our established expertise as a CRO in managing global infectious disease clinical trials, we are deeply committed to hemotune's pioneering strategy for combating septic shock. We recognize the potential for broader applications of their technology to selectively filter harmful agents from the bloodstream. Our team is eager to provide robust support to hemotune throughout the clinical phase of their development program. Our ultimate aim is to facilitate the worldwide availability of the innovative HemoSystem for patients in need."

About hemotune

hemotune is a pioneering biotech company based in Schlieren, Switzerland. Leveraging nanotechnology, hemotune implements precision medicine treatments through its groundbreaking blood purification platform. Founded in 2017 as a spin-off from ETH Zurich, the company has rapidly emerged as a new leader in the field. Recognized for its innovation and impact, hemotune has won numerous awards, including the prestigious Swiss Technology Award 2020 and recognition as a top spin-off to watch by Forbes magazine in 2021. Additionally, in 2022 hemotune has been nominated for the Swiss Economic Award and was awarded the Technology Innovation Leadership Award by Frost and Sullivan underscoring its position as a frontrunner in the healthcare sector. In 2023, hemotune was selected as one of Switzerland's most innovative companies by Bilanz and won two Medical Device Excellence award by GlobalData. hemotune is committed to pushing the boundaries of healthcare and delivering transformative solutions that have the potential to redefine patient care worldwide. For more information, please visit www.hemotune.ch.

About Belmondo

Belmondo Family Office is dedicated to empowering entrepreneurs who are committed to solving real-world problems. With a focus on investing in visionary leaders and disruptive technologies, Belmondo Family Office seeks to support and nurture innovative ventures that have the potential to make a meaningful impact on society. Founded on the belief that entrepreneurial qualities are societal qualities, Belmondo Family Office is committed to fostering a culture of problem-solving, risk-taking, persistence, and nonconformity. By backing entrepreneurs who embody these values, Belmondo Family Office aims to drive positive change and create lasting value for both investors and society as a whole. For more information, please visit www.belmondo.io.

About VP Venture Partners

VP Venture Partners is a private, Zurich-based venture capital firm supporting early-stage life sciences companies in Europe. We focus on human life sciences and invest in medical innovations spanning from Medical Devices, Diagnostics, Digital Health, and Enabling Technologies. We invest in companies that address a high unmet medical need and have an impact on patient's lives, with a passionate and driven team. For more information, please visit <https://www.vpventurepartners.com>

About HEMEX

HEMEX is dedicated to empowering European biotech and medtech companies to successfully navigate their clinical trials. Our mission is to assist these companies at every stage, ensuring that groundbreaking pharmaceuticals, medical devices, and in vitro diagnostics reach the market efficiently. With our headquarters situated near Basel—a global epicenter for Life Sciences—and with additional



regional offices in Germany, Benelux, and the USA, we are strategically positioned to support small and medium-sized enterprises (SMEs). Our comprehensive suite of services includes expert clinical operations, quality management, regulatory guidance, and a spectrum of fundraising options—both dilutive and non-dilutive. At HEMEX, we prioritize swift and clear communication, local accessibility, and unwavering transparency to facilitate the success of our clients. Discover how HEMEX can accelerate your journey from concept to market by visiting us at <https://hemex.ch>.

About OCCIDENT

OCCIDENT is an international venture capital investor with offices in Zug and Munich, is owner-managed and invests own wealth. Its aim is to make a positive contribution to society through sustainable and meaningful investments.

OCCIDENT invests in innovative deep tech start-ups with excellent technologies in the fields of life sciences, digital and high-tech with broad application possibilities and the potential for further value-generating developments. The geographic focus is Germany and Switzerland. The preferred stage for initial financing is from seed rounds or later and from 0.5 million euros. OCCIDENT distinguishes itself in particular by its in-depth knowledge of the technology and the versatile support offered to its portfolio companies by its competent team of experts. For more information, please visit www.occident.group.

Contact

Esther Lenherr

Phone: +41 77 512 36 98

E-Mail: esther.lenherr@hemotune.ch